公开(公告)号：US20190151365A1

公开(公告)日：2019-05-23

申请号：US16321322

申请日：2017-07-28

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Oezlem Anak ,  Sanela Bilic ,  Jennifer Brogdon ,  John Scott Cameron ,  William Chou ,  Stephan Grupp ,  Danny Roland Howard, Jr. ,  Randi Isaacs ,  Carl H. June ,  Simon Lacey ,  Shannon Maude ,  Jan J. Melenhorst ,  Stephen Shuster ,  Alfonso Quintas-Cardama

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.

公开(公告)号：US09982046B2

公开(公告)日：2018-05-29

申请号：US15346026

申请日：2016-11-08

Applicant: NOVARTIS AG

Inventor： Kurt Alex Heldwein ,  Igor Splawski ,  Jennifer Brogdon ,  Joshua Goldstein ,  William Dole ,  John Trauger ,  Chonghui Zhang

IPC: A61P9/08 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  A61K9/00 ,  A61K45/06 ,  C07K14/47 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20170274014A1

公开(公告)日：2017-09-28

申请号：US15327758

申请日：2014-07-21

Applicant: Jennifer Brogdon ,  David Glass ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  David Glass ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy

IPC: A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/32 ,  A61K39/00 ,  A61K39/395

CPC classification number: A61K35/17 ,  A61K31/436 ,  A61K39/12 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/55 ,  A61K2039/55511 ,  A61K2039/70 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C12N5/0638 ,  C12N2501/999 ,  C12N2510/00 ,  C12N2760/16134 ,  A61K2300/00

Abstract: The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to express a CAR.

公开(公告)号：US20170211055A1

公开(公告)日：2017-07-27

申请号：US15327778

申请日：2015-07-21

Applicant: Jennifer Brogdon ,  Carla Guimaraes ,  John Hastewell ,  Andreas Loew ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Carla Guimaraes ,  John Hastewell ,  Andreas Loew

IPC: C12N9/52 ,  C07K16/00

CPC classification number: C12N9/52 ,  C07K16/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/70

Abstract: Sortase molecules and methods described herein allow for the construction of a CAR or CAR member, e.g., in situ, on a CARX, e.g., CART, cell. For example, sortase mediated transfer of an antigen binding domain, e.g., a scFv, onto a CAR member having a sortase acceptor motif in place of an antigen binding domain can provide for a complete CAR member on a cell wherein the cell does not comprise nucleic acid that encodes the complete CAR member.

公开(公告)号：US12186278B2

公开(公告)日：2025-01-07

申请号：US17811606

申请日：2022-07-11

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: C07K16/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20240252538A1

公开(公告)日：2024-08-01

申请号：US18529915

申请日：2023-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  C07K16/28 ,  C12N15/85 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11542488B2

公开(公告)日：2023-01-03

申请号：US15327778

申请日：2015-07-21

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Carla Guimaraes ,  John Hastewell ,  Andreas Loew

IPC: C12N9/52 ,  C12N5/10 ,  C07K16/00

Abstract: Sortase molecules and methods described herein allow for the construction of a CAR or CAR member, e.g., in situ, on a CARX, e.g., CART, cell. For example, sortase mediated transfer of an antigen binding domain, e.g., a scFv, onto a CAR member having a sortase acceptor motif in place of an antigen binding domain can provide for a complete CAR member on a cell wherein the cell does not comprise nucleic acid that encodes the complete CAR member.

公开(公告)号：US20210172020A1

公开(公告)日：2021-06-10

申请号：US16986943

申请日：2020-08-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Felipe Bedoya ,  Hans Bitter ,  Jennifer Brogdon ,  Corin Dorfmeier ,  Abhishek Garg ,  David Jonathan Glass ,  Joan Mannick ,  Jan J. Melenhorst ,  Michael C. Milone ,  Leon Murphy ,  Elena Orlando ,  Nicholas Wilcox

IPC: C12Q1/6886 ,  G01N33/574 ,  C12N5/0783 ,  A61K39/00

Abstract: Cancer biomarkers and methods of using them are disclosed.

公开(公告)号：US10774388B2

公开(公告)日：2020-09-15

申请号：US15517597

申请日：2015-10-07

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Felipe Bedoya ,  Hans Bitter ,  Jennifer Brogdon ,  Corin Dorfmeier ,  Abhishek Garg ,  David Jonathan Glass ,  Joan Mannick ,  Jan J. Melenhorst ,  Michael Milone ,  Leon Murphy ,  Elena Orlando ,  Nicholas Wilcox

IPC: C12Q1/6886 ,  G01N33/574 ,  C12N5/0783 ,  A61K39/00

Abstract: Cancer biomarkers and methods of using them are disclosed.

公开(公告)号：US20190292238A1

公开(公告)日：2019-09-26

申请号：US16256731

申请日：2019-01-24

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: C07K14/705 ,  A61K39/00 ,  C07K16/28 ,  C07K14/725 ,  A61K45/06

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.